ClinicalTrials.gg
CompletedNCT02879617Updated Jan 5, 2024Results posted

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

A Phase 2 interventional study of durvalumab in Non-Small Cell Lung Cancer NSCLC, sponsored by Academic Thoracic Oncology Medical Investigators Consortium. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Academic Thoracic Oncology Medical Investigators Consortium · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
57th of 94
47 · median 74
Started
2017
with 9 others
Phase 2
58 of 94
11 open now
Registered
20th of 94
by date
Lead sponsor
1 of 94
Academic Thoracic Oncology Medical Investigators Consortium

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 57th largest by enrollment, is one of 10 that started in 2017, is one of 58 in phase 2, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 226 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).

Read the detailed description

Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration. Durvalumab will be administered at 1500 mg (fixed dose) every 4 weeks until disease progression, death, unacceptable toxicity or withdrawal of consent for a maximum of 12 months of therapy.

03

Conditions studied

  • Non-Small Cell Lung Cancer NSCLC

Keywords

  • PD-L1 (programmed cell death ligand 1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Patients must have or cytologically confirmed Stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancer.
  • Patients must have .
  • Patients must have not have received any prior therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other agent) for the treatment of stage IV NSCLC.
  • Age ≥ 18 years at time of study entry.
  • performance status of 2.
  • of greater than 12 weeks.
  • Tissue available (archived or fresh tumor ) for the assay.
  • Patients must have normal organ and marrow function as defined below:

    • (ANC) ≥ 1.5 x 10\^9/L (> 1500 per mm\^3)
    • ≥ 9.0 g/dL
    • count ≥ 100 x 10\^9/L (>100,000 per mm\^3)
    • Serum ≤ 1.5 x institutional (ULN).
    • (SGOT)/ALT (SGPT) ≤ 2.5 x ULN unless liver are present, in which case it must be ≤ 5x ULN Serum creatinine CL>40 mL/min by the formula
  • Female subjects must either be of non- OR must have a negative serum pregnancy test upon study entry.
  • The effects of durvalumab on the developing human fetus are unknown. For this reason and because immunomodulatory agents are potentially teratogenic, sexually active women of and men must agree to use adequate (2 methods of effective contraception from screening) from screening, for the duration of study participation, and for at least 90 days following the last infusion of durvalumab.
  • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study; previous enrollment in the present study.
  • Participation in another clinical study with an product for cancer during the last 12 months.
  • Any previous treatment with a PD1 or inhibitor, including durvalumab.
  • Symptomatic or uncontrolled requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or in excess of prednisone 10 mg/d or equivalent.
  • Sensitizing mutations in EGFR or rearrangements in ALK or ROS1.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab.
  • Mean corrected for heart rate (QTc) ≥ 470 ms.
  • Current or prior use of medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids . Patients may be on systemic corticosteroids provided the dose does not exceed prednisone 10 mg/d or equivalent for 1 week prior to study drug administration.
  • Active or prior documented disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
  • History of primary immunodeficiency.
  • History of allogeneic organ transplant.
  • Uncontrolled intercurrent illness.
  • Known history of previous clinical diagnosis of tuberculosis.
  • History of .
  • Receipt of within 30 days prior to study entry or within 30 days of receiving durvalumab.
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
  • Subjects with uncontrolled seizures.
  • Pregnant women; breastfeeding should be discontinued.
  • Prior history of radiation pneumonitis.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    durvalumab

    1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.

    Drug: durvalumab

Interventions

  • A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Median length of time from the start of treatment from start of treatment to death from any cause.

    Time frame: Up to 30 months

  2. Overall Survival (OS12)

    Number of patients alive at 12 months post start of treatment.

    Time frame: At 12 months

  3. Overall Survival (OS24)

    Number of patients alive at 24 months post start of treatment.

    Time frame: At 24 months

  4. Treatment-related Adverse Events ≥ Grade 3

    Number of participants with ≥ Grade 3 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 that are at least possibly related to study treatment.

    Time frame: Up to 30 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Median duration of time from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 30 months

  2. Progression-Free Survival (PFS) at 12 Months

    Number of patients without progressive disease or death at 12 months from start of treatment. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: At 12 months

  3. Progression-Free Survival (PFS) at 24 Months

    Number of patients without progressive disease or death at 24 months from start of treatment Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: At 24 months

  4. Progression-Free Survival (PFS) by PD-L1 Expression at 12 Months

    Number of patients of know PD-L1 status without progressive disease or death at 12 months from start of treatment. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: At 12 months

  5. Progression-Free Survival (PFS) by PD-L1 Expression Status at 24 Months

    Number of patients of know PD-L1 status without progressive disease or death at 24 months from start of treatment Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: At 24 months

  6. Overall Survival by PD-L1 Expression Status at 12 Months

    Number of patients with know PD-L1 status that are alive at 12 months post start of treatment.

    Time frame: At 12 months

  7. Overall Survival by PD-L1 Expression Status at 24 Months

    Number of patients with know PD-L1 status that are alive at 24 months post start of treatment.

    Time frame: At 24 months

  8. Overall Response Rate (ORR)

    Percentage of patients with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0, for target lesions: PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: at least a 20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 30 months

  9. Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0

    Percentage of patients with PD-L1 expression status = 0, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 30 months

  10. Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0%<PD-L1<50%.

    Percentage of patients with PD-L1 expression status=0%\<PD-L1\<50%, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 30 months

  11. Overall Response Rate (ORR) in Patients With PD-L1 Expression Status ≥50%

    Percentage of patients with PD-L1 expression status ≥50%, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Up to 30 months

  12. Health Related Quality of Life (HRQL) - FACT-G

    Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At baseline

  13. Health Related Quality of Life (HRQL) - FACT-G

    Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: Within first two treatment cycles, up to 56 days

  14. Health Related Quality of Life (HRQL) - FACT-G

    Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At 6 months

  15. Health Related Quality of Life (HRQL) - FACT-G

    Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At 12 months

  16. FACT Lung Cancer Subscale (LCS)

    The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At baseline

  17. FACT Lung Cancer Subscale (LCS)

    The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: Within first two treatment cycles, up to 56 days

  18. FACT Lung Cancer Subscale (LCS)

    The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At 6 months

  19. FACT Lung Cancer Subscale (LCS)

    The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

    Time frame: At 12 months

07

Results

Posted Oct 24, 2023

Participant flow

Registered for study.

Participant flow — Overall Study
MilestoneDurvalumab
Started47
Completed47
Not completed0

Outcome measures

PrimaryOverall Survival (OS)

Median length of time from the start of treatment from start of treatment to death from any cause.

Time frame:
Up to 30 months
Reported as:
Median · months
Overall Survival (OS)
monthsDurvalumab
Overall Survival (OS)6.00 (4.00 to 10.00)
PrimaryOverall Survival (OS12)

Number of patients alive at 12 months post start of treatment.

Time frame:
At 12 months
Reported as:
Number · participants
Overall Survival (OS12)
participantsDurvalumab
Overall Survival (OS12)15
PrimaryOverall Survival (OS24)

Number of patients alive at 24 months post start of treatment.

Time frame:
At 24 months
Reported as:
Number · participants
Overall Survival (OS24)
participantsDurvalumab
Overall Survival (OS24)8
PrimaryTreatment-related Adverse Events ≥ Grade 3

Number of participants with ≥ Grade 3 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 that are at least possibly related to study treatment.

Time frame:
Up to 30 months
Reported as:
Count of participants · Participants
Treatment-related Adverse Events ≥ Grade 3
ParticipantsDurvalumab
EYE DISORDERS - Optic Nerve Leak1
GASTROINTESTINAL DISORDERS - Colitis1
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Fatigue1
CARDIAC DISORDERS - Cardiac arrest1
INVESTIGATIONS - Lipase increased1
METABOLISM AND NUTRITION DISORDERS - Hyponatremia1
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Pneumonitis2
INVESTIGATIONS - Lymphocyte count decreased1
SecondaryProgression-Free Survival (PFS)

Median duration of time from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 30 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsDurvalumab
Progression-Free Survival (PFS)3.00 (1.00 to 4.00)
SecondaryProgression-Free Survival (PFS) at 12 Months

Number of patients without progressive disease or death at 12 months from start of treatment. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
At 12 months
Reported as:
Number · participants
Progression-Free Survival (PFS) at 12 Months
participantsDurvalumab
Progression-Free Survival (PFS) at 12 Months7
SecondaryProgression-Free Survival (PFS) at 24 Months

Number of patients without progressive disease or death at 24 months from start of treatment Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
At 24 months
Reported as:
Number · participants
Progression-Free Survival (PFS) at 24 Months
participantsDurvalumab
Progression-Free Survival (PFS) at 24 Months4
SecondaryProgression-Free Survival (PFS) by PD-L1 Expression at 12 Months

Number of patients of know PD-L1 status without progressive disease or death at 12 months from start of treatment. Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
At 12 months
Reported as:
Number · participants
Progression-Free Survival (PFS) by PD-L1 Expression at 12 Months
participantsDurvalumab
PD-L1=01
0%<PD-L1<50%4
PD-L1≥50%2
SecondaryProgression-Free Survival (PFS) by PD-L1 Expression Status at 24 Months

Number of patients of know PD-L1 status without progressive disease or death at 24 months from start of treatment Per RECIST v1.0 Progressive Disease (PD) for target lesions: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions:Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
At 24 months
Reported as:
Number · participants
Progression-Free Survival (PFS) by PD-L1 Expression Status at 24 Months
participantsDurvalumab
PD-L1=00
0%<PD-L1<50%3
PD-L1≥50%1
SecondaryOverall Survival by PD-L1 Expression Status at 12 Months

Number of patients with know PD-L1 status that are alive at 12 months post start of treatment.

Time frame:
At 12 months
Reported as:
Number · participants
Overall Survival by PD-L1 Expression Status at 12 Months
participantsDurvalumab
PD-L1=05
0%<PD-L1<50%5
PD-L1≥50%3
SecondaryOverall Survival by PD-L1 Expression Status at 24 Months

Number of patients with know PD-L1 status that are alive at 24 months post start of treatment.

Time frame:
At 24 months
Reported as:
Number · participants
Overall Survival by PD-L1 Expression Status at 24 Months
participantsDurvalumab
PD-L1=03
0%<PD-L1<50%3
PD-L1≥50%2
SecondaryOverall Response Rate (ORR)

Percentage of patients with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0, for target lesions: PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: at least a 20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsDurvalumab
Partial Response (PD)26
Stable Disease (SD)47
Progressive Disease (PD)26
SecondaryOverall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0

Percentage of patients with PD-L1 expression status = 0, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0
percentage of participantsDurvalumab
Partial Response31
Stable Disease38
Progressive Disease31
SecondaryOverall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0%<PD-L1<50%.

Percentage of patients with PD-L1 expression status=0%\<PD-L1\<50%, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0%<PD-L1<50%.
percentage of participantsDurvalumab
Partial Response30
Stable Disease60
Progressive Disease10
SecondaryOverall Response Rate (ORR) in Patients With PD-L1 Expression Status ≥50%

Percentage of patients with PD-L1 expression status ≥50%, with a Best Response of Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). Per RECIST v1.0 (target lesions): PR: ≥30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither PR nor PD (target lesions); persistence of 1 or more non-target lesions and/or the maintenance of tumor marker levels above normal limits. PD: ≥20% increase in sum of diameters (target lesions), taking as reference the smallest sum on study (includes baseline sum if smallest on study). In addition to relative increase of 20%, sum must demonstrate absolute increase of at least 5 mm. (includes appearance of one or more new lesions) ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
Up to 30 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in Patients With PD-L1 Expression Status ≥50%
percentage of participantsDurvalumab
Partial Response25
Stable Disease25
Progressive Disease50
SecondaryHealth Related Quality of Life (HRQL) - FACT-G

Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At baseline
Reported as:
Mean · score on a scale
Health Related Quality of Life (HRQL) - FACT-G
score on a scaleDurvalumab
Health Related Quality of Life (HRQL) - FACT-G78.2908 ± 16.1690
SecondaryHealth Related Quality of Life (HRQL) - FACT-G

Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
Within first two treatment cycles, up to 56 days
Reported as:
Mean · score on a scale
Health Related Quality of Life (HRQL) - FACT-G
score on a scaleDurvalumab
Health Related Quality of Life (HRQL) - FACT-G76.6788 ± 16.8937
SecondaryHealth Related Quality of Life (HRQL) - FACT-G

Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At 6 months
Reported as:
Mean · score on a scale
Health Related Quality of Life (HRQL) - FACT-G
score on a scaleDurvalumab
Health Related Quality of Life (HRQL) - FACT-G80.5103 ± 17.8968
SecondaryHealth Related Quality of Life (HRQL) - FACT-G

Patient self-administered 27-item questionnaire that measures health state in cancer patients in prior 7 days, including physical, social, emotional, and functional well-being. Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-108. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At 12 months
Reported as:
Mean · score on a scale
Health Related Quality of Life (HRQL) - FACT-G
score on a scaleDurvalumab
Health Related Quality of Life (HRQL) - FACT-G80.0166 ± 13.3727
SecondaryFACT Lung Cancer Subscale (LCS)

The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At baseline
Reported as:
Mean · score on a scale
FACT Lung Cancer Subscale (LCS)
score on a scaleDurvalumab
FACT Lung Cancer Subscale (LCS)18.5 ± 5.52268
SecondaryFACT Lung Cancer Subscale (LCS)

The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
Within first two treatment cycles, up to 56 days
Reported as:
Mean · score on a scale
FACT Lung Cancer Subscale (LCS)
score on a scaleDurvalumab
FACT Lung Cancer Subscale (LCS)17.4090 ± 5.69679
SecondaryFACT Lung Cancer Subscale (LCS)

The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At 6 months
Reported as:
Mean · score on a scale
FACT Lung Cancer Subscale (LCS)
score on a scaleDurvalumab
FACT Lung Cancer Subscale (LCS)19.6346 ± 3.32909
SecondaryFACT Lung Cancer Subscale (LCS)

The FACT-LCS is the lung cancer subscale of the FACT-L. LCS includes the average symptom burden index (ASBI; based on 5 symptoms: anorexia, fatigue, cough, dyspnea, hemoptysis, and pain) and the 3-item global index (2-IGI; symptom distress, interference with activities, and health-related quality of life). Scoring: Five-point scale: 0 (not at all) to 4 (very much). Total score is from 0-28. Questions are phrased so that higher numbers indicate a better health state, leading to some items being reverse-scored.

Time frame:
At 12 months
Reported as:
Mean · score on a scale
FACT Lung Cancer Subscale (LCS)
score on a scaleDurvalumab
FACT Lung Cancer Subscale (LCS)17.9444 ± 2.92024

Adverse events

Collected over Adverse Events data were collected for up to 33 months per patient, and up to. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab40/47 (85.1%)26/47 (55.3%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventDurvalumab
DyspneaRespiratory, thoracic and mediastinal disorders11/47
Lung infectionInfections and infestations10/47
HypoxiaRespiratory, thoracic and mediastinal disorders8/47
Pleural effusionRespiratory, thoracic and mediastinal disorders5/47
Atrial fibrillationCardiac disorders4/47
Respiratory failureRespiratory, thoracic and mediastinal disorders4/47
AnemiaBlood and lymphatic system disorders2/47
Cardiac arrestCardiac disorders2/47
Non-cardiac chest painGeneral disorders2/47
Urinary tract infectionInfections and infestations2/47
Most frequent other events
Showing 10 of 261
Most frequent other events
EventDurvalumab
AnemiaBlood and lymphatic system disorders30/47
HypoalbuminemiaMetabolism and nutrition disorders26/47
Lymphocyte count decreasedInvestigations23/47
FatigueGeneral disorders20/47
DyspneaRespiratory, thoracic and mediastinal disorders18/47
HyponatremiaMetabolism and nutrition disorders17/47
ProteinuriaRenal and urinary disorders15/47
HypertensionVascular disorders15/47
Alkaline phosphatase increasedInvestigations14/47
Sinus tachycardiaCardiac disorders13/47

Baseline characteristics

All treated patients.

Age, Continuous
Age, Continuous(years)Durvalumab
Mean76.4 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab
Female20
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab
Hispanic or Latino1
Not Hispanic or Latino7
Unknown or Not Reported39
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White46
More than one race0
Unknown or Not Reported0
Smoking Status
Smoking Status(Participants)Durvalumab
Former36
Current10
Never1
Histology
Histology(Participants)Durvalumab
ADENOCARCINOMA, METASTATIC, NOS7
ADENOCARCINOMA, N/A2
ADENOCARCINOMA, NOS16
BASALOID SQUAMOUS CELL CARCINOMA1
METASTATIC ADENOSQUAMOUS CARCINOMA2
NEOPLASM, MALIGNANT2
NON-SMALL CELL CA5
PLEOMORPHIC CARCINOMA1
SQUAMOUS CELL CA METASTATIC, NOS3
SQUAMOUS CELL CA, LG CELL, NONKER, MET1
SQUAMOUS CELL CARCINOMA, NOS7
ECOG Performance Status = 2
ECOG Performance Status = 2(Participants)Durvalumab
Count of participants47
Disease Stage
Disease Stage(Participants)Durvalumab
STAGE IIIB6
STAGE IV38
STAGE IVB3
08

Study locations

2 sites
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Simmons Comprehensive Cancer Center - UT Southwestern Medical Center
    Dallas, Texas 75390, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article after deidentification, in addition to the Study Protocol, will be available immediately following publication. Investigators whose proposed use of the data has been approved by an independent review committee may access the data to achieve aims in the approved proposal. Proposals should be directed to villaruzl@upmc.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years after publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data are available for 5 years after publication.

Access criteria: Proposals should be directed to villaruzl@upmc.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jun 2022, 62 months.

Results were first posted in Oct 2023, 1 year 4 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 62 months is above that.

Counting every sponsor, half of 1,048 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2016
First posted
Aug 25, 2016
StartActual
Apr 4, 2017
Primary completionActual
Jun 4, 2022
CompletionActual
Jun 4, 2022
Results first posted
Oct 24, 2023
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02879617
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Collaborators
AstraZeneca
Responsible party
Liza Villaruz (Assistant Professor of Medicine, Division of Hematology Oncology, University of Pittsburgh) — Principal investigator
First posted
Aug 25, 2016
Start date
Apr 4, 2017
Primary completion
Jun 4, 2022
Completion
Jun 4, 2022
Results posted
Oct 24, 2023
Last update
Jan 5, 2024

Study contacts

Liza Villaruz, MD
principal investigator · University of Pittsburgh Cancer Institute, Department of Hematology Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion